Twenty-four-hour blood pressure monitoring after a single dose of sustained-release verapamil.
The antihypertensive effect of a single dose of 240 mg sustained-release (S-R) verapamil was investigated by ambulatory blood pressure (BP) monitoring in 13 patients with mild to moderate essential hypertension. Following a 2-week washout period, 24-hour BP monitoring was carried out with a Spacelabs ICR 5300 device following random administration of a tablet of S-R verapamil or placebo; BP recording was repeated after crossover 3 to 7 days later. Average whole-day systolic and diastolic BPs were significantly lower after verapamil (130.1 +/- 2.6/87.1 +/- 1.2 mmHg) than after placebo (142.1 +/- 3.3/95.8 +/- 2.1 mmHg) (p less than 0.01). Mean waking BP was 146.4 +/- 3.6/99.1 +/- 2.2 mmHg after placebo and 135.2 +/- 3.3/90.5 +/- 1.7 mmHg after verapamil (p less than 0.01); during sleeping hours BP was 133.8 +/- 3.1/88.7 +/- 2.6 mmHg following placebo and 122.2 +/- 2.3/80.9 +/- 1.8 mmHg following verapamil (p less than 0.01). Blood pressure profile was significantly reduced by verapamil up to 20 hours after tablet administration, while from 21 to 24 hours after drug intake BP values were similar to placebo. Response to verapamil was not correlated to the pretreatment BP values and to the patient's age. In summary, this study suggests that acute administration of 240 mg S-R verapamil in hypertensive patients produces a BP reduction during 24-hour, daytime, and nighttime periods. The hypotensive efficacy is preserved for many hours after tablet intake and seems to be due to individual variation in cardiovascular reactivity to the drug.